The Hindu Business Line : 'Target mid-sized pharma cos in the US'

MERGERS and acquisitions in the Indian pharma scene are expected to speed up in the next three years. The activity will be particularly high in biotechnology industry as well, a report on healthcare by ABN Amro Bank said here on Wednesday.

Indian companies are expected to witness an immediate gain if they target mid-sized pharma companies in the US and Europe to expand their bases to the global arena as well, said Mr Ton Gardeniers, Managing Director-Global Head Healthcare, ABN-Amro. ``In the next one and a half years, the M&A activity particularly in the generic segment is set to increase. This trend will continue for a three-year time period in the biotechnology industry considering the regulatory framework and maturity of the sector in India,'' he added.

With the wave of blockbuster patent expiration slowing down post 2005, strong growth in the global pharma industry may become difficult. ``Very strong growth is expected through 2005-06. However, post 2005, growth may become difficult as size of market has become very large,'' he added.

Article E-Mail :: Comment :: Syndication

Stories in this Section
Natco bags Rs 35-crore export order

BHEL bags turbine order from Gujarat Ambuja

Sujana group cos plan pref offers

GAIL, GSPC tussle over Ahmedabad block continues

Audit firm rotation in listed cos likely

Tata Engg plans $90-m FCCB issue

As Finance Ministry, RBI step in - Time frame set for Haldia Petro debt revamp

Rayalaseema Alkalies okays debt revamp package

'Target mid-sized pharma cos in the US'

Malu Fin buys 8% stake in Padmalaya

LML to double motorbike output; plans new models

ITH Q1 billing up 15%